Additionally, more in-depth analysis of metabolic pathways altered in osimertinib- and erlotinib-resistant cell lines could shed light on how NSCLC becomes resistant to first and third generation EGFR TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.